The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e.
AUC) is increased when osimertinib is co-administered with cobicistat in patients with
relatively low plasma trough concentration while receiving the standard osimertinib dose.
Phase:
Early Phase 1
Details
Lead Sponsor:
Academisch Ziekenhuis Maastricht
Collaborators:
The Netherlands Cancer Institute ZonMw: The Netherlands Organisation for Health Research and Development